Filing Flows › Neurocrine Biosciences (NBIX) › Free cash flow
Neurocrine Biosciences (NBIX) free cash flow by quarter
Neurocrine Biosciences' free cash flow was $384M in Q3 2026 (third quarter 2026), +198% from Q2 2026. Over the last 6 quarters it ranged from $54.1M (Q1 2025) to $384M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $384M | +198% | +79% |
| Q2 2026 | $129M | -6% | +44% |
| Q1 2026 | $137M | -36% | +153% |
| Q3 2025 | $214M | +139% | — |
| Q2 2025 | $89.5M | +65% | — |
| Q1 2025 | $54.1M | — | — |
Q3 2026 at a glance
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neurocrine Biosciences' free cash flow?
Neurocrine Biosciences' free cash flow was $384M in Q3 2026 (third quarter 2026), +198% from Q2 2026.
How has Neurocrine Biosciences' free cash flow changed?
Over the last 6 quarters it ranged from $54.1M (Q1 2025) to $384M (Q3 2026).
Q3 2026 results → · How Neurocrine Biosciences makes money →